Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab in advanced esophageal and gastric cancer
NCT00130689Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jul 2005
- Primary completion
- Sep 2010
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in esophageal cancer, gastric cancer (GC), sponsored by Dana-Farber Cancer Institute. Started Jul 2005; status: completed.
02
Drugs
cetuximab
03
Conditions
esophageal cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT00130689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00130689.